The Journal of clinical endocrinology and metabolism · 2026
Elevated Risk of New-Onset Thyroid Disease Associated With SARS-CoV-2 Infection: A 4.5-Year Observational Study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mehrotra-Varma Shiv, Hadidchi Roham, Henry Sonya S, Nguyen Hien Quang, Mehrotra-Varma Jai, Coard Michael C, Changela Sagar, Collins Jessilin, Duong Tim Q
Аннотация
CONTEXT: Thyroid disease has been reported as a complication associated with acute SARS-CoV-2 infection.
OBJECTIVE: This study evaluated the long-term risk of incident thyroid dysfunction after COVID-19 in patients without preexisting thyroid disease.
METHODS: Patients without prior thyroid disease were grouped into 15 372 individuals hospitalized with COVID-19, 41 757 nonhospitalized individuals with COVID-19, 343 348 contemporary COVID-negative controls (March 1, 2020-August 17, 2024), and 171 141 historical controls (January 1, 2016-December 31, 2019) within the Montefiore Health System. Outcomes included new-onset thyroid disease, hypothyroidism, hyperthyroidism, and other/unspecified thyroid disease, and thyrotropin (TSH), free 3,5,3'-triiodothyronine (FT3), and free thyroxine (FT4) levels. The primary analysis used Cox regression with inverse probability weighting (IPW). Sensitivity analyses included multivariate adjustment, 1:1 propensity score matching, and comparisons with historical controls.
RESULTS: Compared to contemporary COVID-negative controls, patients hospitalized for COVID-19 had significantly higher risk of all thyroid disease (IPW-adjusted hazard ratio (HR) = 2.11 [2.03-2.19]), hypothyroidism (HR = 2.02 [1.92-2.12]), hyperthyroidism (HR = 2.31 [2.13-2.50]), and other/unspecified thyroid disease (HR = 2.27 [2.12-2.43]). Nonhospitalized COVID-positive patients also had increased risk of all thyroid disease (HR = 1.40 [1.35-1.46]), hypothyroidism (HR = 1.37 [1.31-1.43]), hyperthyroidism (HR = 1.56 [1.45-1.68]), and other/unspecified thyroid disease (HR = 1.42 [1.34-1.51]). Sensitivity analyses were consistent with the main findings. Estimates of risks were attenuated in the nonhospitalized cohort when compared to historical controls.
CONCLUSION: SARS-CoV-2 infection is associated with an increased risk of all forms of new-onset thyroid disease investigated both in hospitalized and nonhospitalized patients. These findings suggest that enhanced screening for thyroid dysfunction may be warranted among individuals recovering from COVID-19.
OBJECTIVE: This study evaluated the long-term risk of incident thyroid dysfunction after COVID-19 in patients without preexisting thyroid disease.
METHODS: Patients without prior thyroid disease were grouped into 15 372 individuals hospitalized with COVID-19, 41 757 nonhospitalized individuals with COVID-19, 343 348 contemporary COVID-negative controls (March 1, 2020-August 17, 2024), and 171 141 historical controls (January 1, 2016-December 31, 2019) within the Montefiore Health System. Outcomes included new-onset thyroid disease, hypothyroidism, hyperthyroidism, and other/unspecified thyroid disease, and thyrotropin (TSH), free 3,5,3'-triiodothyronine (FT3), and free thyroxine (FT4) levels. The primary analysis used Cox regression with inverse probability weighting (IPW). Sensitivity analyses included multivariate adjustment, 1:1 propensity score matching, and comparisons with historical controls.
RESULTS: Compared to contemporary COVID-negative controls, patients hospitalized for COVID-19 had significantly higher risk of all thyroid disease (IPW-adjusted hazard ratio (HR) = 2.11 [2.03-2.19]), hypothyroidism (HR = 2.02 [1.92-2.12]), hyperthyroidism (HR = 2.31 [2.13-2.50]), and other/unspecified thyroid disease (HR = 2.27 [2.12-2.43]). Nonhospitalized COVID-positive patients also had increased risk of all thyroid disease (HR = 1.40 [1.35-1.46]), hypothyroidism (HR = 1.37 [1.31-1.43]), hyperthyroidism (HR = 1.56 [1.45-1.68]), and other/unspecified thyroid disease (HR = 1.42 [1.34-1.51]). Sensitivity analyses were consistent with the main findings. Estimates of risks were attenuated in the nonhospitalized cohort when compared to historical controls.
CONCLUSION: SARS-CoV-2 infection is associated with an increased risk of all forms of new-onset thyroid disease investigated both in hospitalized and nonhospitalized patients. These findings suggest that enhanced screening for thyroid dysfunction may be warranted among individuals recovering from COVID-19.